LXRX Lexicon Pharmaceuticals Inc

Price (delayed)

$2.41

Market cap

$442.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.65

Enterprise value

$444.72M

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes ...

Highlights
Lexicon Pharmaceuticals's gross margin has increased by 10% YoY
LXRX's debt has surged by 102% year-on-year
LXRX's revenue has plunged by 98% YoY and by 65% from the previous quarter

Key stats

What are the main financial stats of LXRX
Market
Shares outstanding
183.63M
Market cap
$442.54M
Enterprise value
$444.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.09
Price to sales (P/S)
3,308.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,079.99
Earnings
Revenue
$109,000
EBIT
-$95.52M
EBITDA
-$95.09M
Free cash flow
-$88.13M
Per share
EPS
-$0.65
Free cash flow per share
-$0.59
Book value per share
$0.47
Revenue per share
$0
TBVPS
$0.45
Balance sheet
Total assets
$112.33M
Total liabilities
$41.5M
Debt
$23.63M
Equity
$70.83M
Working capital
$48.04M
Liquidity
Debt to equity
0.33
Current ratio
3.85
Quick ratio
3.68
Net debt/EBITDA
-0.02
Margins
EBITDA margin
-87,236.7%
Gross margin
100%
Net margin
-88,803.7%
Operating margin
-87,778.9%
Efficiency
Return on assets
-69.4%
Return on equity
-93.6%
Return on invested capital
-350.3%
Return on capital employed
-100.1%
Return on sales
-87,630.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LXRX stock price

How has the Lexicon Pharmaceuticals stock price performed over time
Intraday
-5.49%
1 week
1.69%
1 month
-12.68%
1 year
-50.92%
YTD
-38.83%
QTD
29.57%

Financial performance

How have Lexicon Pharmaceuticals's revenue and profit performed over time
Revenue
$109,000
Gross profit
$109,000
Operating income
-$95.68M
Net income
-$96.8M
Gross margin
100%
Net margin
-88,803.7%
LXRX's revenue has plunged by 98% YoY and by 65% from the previous quarter
The company's gross profit has shrunk by 98% YoY and by 65% QoQ
Lexicon Pharmaceuticals's gross margin has increased by 10% YoY
The net income has decreased by 7% from the previous quarter

Growth

What is Lexicon Pharmaceuticals's growth rate over time

Valuation

What is Lexicon Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.09
P/S
3,308.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,079.99
The company's EPS fell by 4.8% QoQ
Lexicon Pharmaceuticals's equity has decreased by 48% YoY and by 24% QoQ
The P/B is 16% higher than the last 4 quarters average of 4.4
LXRX's revenue has plunged by 98% YoY and by 65% from the previous quarter
LXRX's price to sales (P/S) is 91% more than its last 4 quarters average of 1735.8

Efficiency

How efficient is Lexicon Pharmaceuticals business performance
LXRX's ROIC is up by 29% from the previous quarter
The company's return on equity fell by 24% QoQ
LXRX's ROA is down by 19% QoQ

Dividends

What is LXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LXRX.

Financial health

How did Lexicon Pharmaceuticals financials performed over time
The total assets is 171% greater than the total liabilities
The total assets has declined by 35% year-on-year and by 18% since the previous quarter
LXRX's total liabilities is up by 20% year-on-year but it is down by 4.6% since the previous quarter
LXRX's debt is 67% smaller than its equity
LXRX's debt has surged by 102% year-on-year
Lexicon Pharmaceuticals's equity has decreased by 48% YoY and by 24% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.